Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPM CD19 CAR-T for Advanced Lymphoid Malignancies
NCT04844086Phase 1Terminated
- Sponsor
- Eden BioCell Ltd.
- Start
- Mar 2021
- Primary completion
- May 2022
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RPM CD19-mbIL15-CAR-T in B cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and 3 more, sponsored by Eden BioCell Ltd. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Mar 2021; status: terminated.
02
Drugs
RPM CD19-mbIL15-CAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04844086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04844086.